United Therapeutics Acquires George Church-Backed Thymmune Therapeutics for Up to $300 Million to Advance Regenerative Thymic Cell Therapy

Jul 04, 2026 10:43 CST Updated 10:43

United Therapeutics

Pharmaceutical R&D Developer

Thymmune

Developer of Scalable Thymocyte Therapy

On July 2, United Therapeutics (Nasdaq: UTHR) announced the acquisition of Thymmune Therapeutics, a privately held preclinical-stage biotechnology company developing scalable regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiency, and autoimmune diseases, for $300 million.United Therapeutics was founded in 1996 by CEO Martine Rothblatt with the aim of discovering a treatment for her daughter’s life-threatening rare disease, pulmonary arterial hypertension. The company has transformed the treatment of rare diseases and pioneered alternative solutions to expand the supply of transplantable organs. United TherapeuticsMostNew Market Cap$23.5 billion. (Emerging Star! George Church Founds Company, Raises $7 Million to Develop Thymus Cell Therapy Platform）

Thymmune, founded in 2019, is developing a pipeline of therapies for immunodeficiency, transplantation-related, and autoimmune diseases, building on decades of thymus research.Thymmune isThymmune, a company co-founded by renowned geneticist George Church and his postdoctoral fellow Stan Wang. His recent ventures include Colossal Biosciences, Manifold Bio, and Rejuvenate Bio.Completed a $7 million seed financing round in 2023, with investors includingPillar VC、NYBC Ventures、Mark Bamforth and James Fordyce, founders of Brammer Bio and Arranta Bio,Alnylam's Founding Former CEODr. John Maraganore, Judy Pagliuca of PagsGroup, Dr. Philip Reilly, and the company’s scientific advisor, Dr. George Church. September 2023Thymmune Receives $37 Million in Funding from the Advanced Research Projects Agency for Health (ARPA-H) of the U.S. National Institutes of Health.Thymmune in its initial years willStan Wangtransforming postdoctoral research into a platform that integrates machine learning with induced pluripotent stem cell engineering.

The thymus is a critical organ for the development and normal function of key components of the immune system, including the training of T cells, which is essential for combating infections and other diseases. Thymmune has a proprietary process that converts human induced pluripotent stem cells (iPSCs) into thymic progenitor cells, which, upon engraftment in the body, mature into cell types capable of restoring healthy T-cell function.

Thymmune’s lead candidate, THY-100, is currently in preclinical development for congenital athymia, an ultra-rare and life-threatening condition in which infants are born without a functional thymus. Animal studies have demonstrated that treatment with THY-100 can induce the formation of new thymic tissue in vivo capable of supporting T-cell development. Clinical proof-of-concept and further development of THY-100 have the potential to expand thymus regenerative medicine approaches to applications such as transplant tolerance, severe immune-mediated diseases, and extending the lifespan of older adults with diminished T-cell function.

Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, stated:“Thymmune’s platform complements United Therapeutics’ broader mission to expand the supply of transplantable organs, building on our UThymoKidney™ clinical development program and our growing strength in immunomodulatory therapies. By restoring or modulating T-cell receptor diversity, Thymmune’s technology has the potential to make a fundamental contribution to human healthcare and address the root causes of dozens of life-threatening diseases.”

Dr. Stan Wang, CEO and Founder of Thymmune Therapeutics, stated:“Thymmune was established to harness the biology of the thymus to restore immune function in patients with severe immune-mediated diseases. United Therapeutics shares our belief that regenerative medicine can transform patients’ lives, and we believe its leadership in organ replacements and cell-based technologies makes it an ideal partner to propel our platform toward broad clinical impact.”

Pursuant to the terms of the agreement, United Therapeutics acquired Thymmune for $140 million in cash, subject to certain post-closing adjustments. Additionally, up to $160 million in milestone payments may be paid to former Thymmune equity holders upon the achievement of certain clinical and regulatory milestones by the end of 2031.

Follow the official account below to see the world!